Matched tumor tissue and plasma mutation statuses were available for 194 patients for EGFR and 135 patients for KRAS. A comparison of the EGFR and KRAS mutation status between the tumor biopsies and plasma samples is summarized in Table 2. This evidence concerns the gene KRAS and neoplasm.